Last update July 16, 2022
Very Low Risk
Canakinumab es un anticuerpo monoclonal humano recombinante contra la interleucina-1β que se utiliza para el tratamiento de la artritis gotosa, la artritis juvenil y los síndromes de fiebre periódica. Administración subcutánea cada 4 a 12 semanas.
Its very high molecular weight explain the null or negligible passage to breast milk observed. (Weber 2022, Bosshard 2021)
No clinical problems or a higher rate of infections and no problems with routine vaccinations have been observed in infants of mothers receiving this drug. (Weber 2022, İlgen 2022, Bosshard 2021, Youngstein 2017)
Due to its protein nature, it is inactivated in the gastrointestinal tract, not being absorbed (practically nil oral bioavailability), which hinders or prevents the passage into plasma of the infant from ingested breast milk (Lactmed), except in premature infants and during the immediate neonatal period, in which there may be greater intestinal absorption.
We do not have alternatives for Canakinumab since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM